Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial

Fig. 2

Characterization and quality control for UC-MSC. A Representative image of cell differentiation. (a, c, e) Control cells; (b) Cells differentiated into adipocytes characterized by the presence of lipidic vacuoles stained with Oil Red O; (d) Cells differentiated into osteoblasts characterized by the presence of calcium deposits stained with Alizarin Red S (red); (f) Presence of vacuoles around young chondrocytes and proteoglycan in the matrix. B Representative histograms of UC-MSC surface markers, cell viability and apoptosis/necrosis. The isotype control is shown as a red line histogram. C UC-MSC karyogram after cell expansion. Normal karyotype: 46, XX. D Representative histograms from the lymphocyte inhibition assay. MSCs were cultivated with PHA stimulated CD3 + lymphocytes labeled with CFSE. (a) CD3 + lymphocytes not labeled with CFSE; (b) CFSE-labeled CD3 + lymphocytes; (c) CD3 + lymphocytes labeled with CFSE and stimulated with PHA (1 µg/µL); (d) MSCs were cultivated with CD3 + lymphocytes labeled with CFSE 1:10; (e) MSCs were cultivated with CD3 + lymphocytes labeled with CFSE 1:5; (f) MSCs were cultivated with CD3 + lymphocytes labeled with CFSE in a 1:2 ratio

Back to article page